40, Dalton St

Boston,

MA,

USA,

ZIP: 02115

Phone: +16174554188

In the wake of new FDA guidance and exciting MRD partnership announcements between Grail and AstraZeneca, Amgen and Bristol Myers Squibb the liquid biopsy industry is experiencing a paradigm shift. Touted as having the potential to transform clinical practice as we know it, technical progress and mounting investment in premetastatic applications are creating huge industry-wide excitement for liquid biopsy-based screening and surveillance for novel precision drug development.

With technology maturity on the near horizon, the inaugural Liquid Biopsy Surveillance and Early Detection Summit is your only dedicated platform providing much-needed clarity on the industry's emerging assays increasingly opening the doors to novel trial design and better patient outcomes.

As drug and diagnostic developers look to realize the commercial impact of early detection and MRD while shifting pipelines from the metastatic setting, here lies your best opportunity to harness game-changing technologies to define leading stratification, surrogate endpoint, and regulatory strategies - accelerating the delivery of breakthrough therapies into the clinic.

Providing a path forward for early detection and surveillance to become a widespread patient reality, unite with 80+ Translational, Biomarker, Clinical, Regulatory, Precision Medicine, Medical Affairs and Diagnostic experts at your only forum prioritizing liquid biopsy applications for earlier intervention.

Ensure you and your team stay ahead of the curve with unmissable intelligence November!

URLs:
Tickets: https://go.evvnt.com/1315351-2?pid=1052
Brochure: https://go.evvnt.com/1315351-3?pid=1052

Prices:
Drug Developers and Academics Conference Pass: USD 0.50,
Commercial Vendors Conference Pass: USD 3599.00,
Technical Vendors Conference Pass: USD 2599.00

Aadel Chaudhuri, Assistant Professor of Radiation Oncology, Washington University School of Medicine, Arnab Basu, Medical Oncologist, O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Carl Barrett, Vice President, Translational Science, Oncology R and D, AstraZeneca, Dave Cescon, Clinician Scientist, Princess Margaret Cancer Centre, Diana Merino, Vega Director, Oncology Translational Medicine Strategy and Portfolio, AstraZeneca, Gary Kelloff, Special Advisor, Cancer Imaging Program, National Cancer Institute, Islam Mohamed, Clinical Assistant Professor, University of British Columbia, Jean-François Martini, Executive Director, Translational Oncology Lead, Global Product Development, Oncology, Pfizer, Johan Skog, Chief Scientific Officer and Vice President, ExosomeDx, a Bio-Techne Brand, Leah Fine, Senior Director, Centers of Excellence Program, GO2 Foundation for Lung Cancer, Lourdes Barrera, Executive Director, Global Medical Affairs, Oncology, Precision Medicine, Merck, Matt Davis, Senior Director, Molecular Biology and Sequencing, Gritstone bio, Mohan Bolisetty, WW Medical Lead, Bristol Myers Squibb, Panna Sharma, Chief Executive Officer, President and Board Member, Lantern Pharma, Pashtoon Kasi, Assistant Professor of Medicine, Weill Cornell Medical College, Stephen Ezell, Vice President, Global Innovation Policy, Information Technology and Innovation Foundation, Zheng Feng, Director, Global Clinical Biomarkers and Companion Diagnostics, Global Development, EMD Serono